Scientist Kills Child In Frankenstein Gene Editing Experiment

Scientist pipetting blue liquid into test tubes
Photo: YanLev Alexey Sizov / Shutterstock

A six-year-old girl died after an experimental gene therapy, and Shanghai investigators now say the scientists running the trial knew about serious warning signs before she died and still kept her death out of their published research.

Quick Take

  • A Shanghai investigation found the girl died March 31, 2025, from a blood-clotting complication linked to the gene therapy she received.
  • Researchers reportedly failed to pass along warning signs from animal testing before treating her.
  • State media reports the team left the girl’s death out of a study published in February.
  • Lead researcher Qiu Zilong was fired and barred from government science projects for five years; another researcher was also dismissed.

What Shanghai Investigators Found

Shanghai’s municipal work group concluded the girl developed a high fever and kidney damage after receiving the experimental treatment. She died on March 31, 2025. An emergency ethics review two days later blamed her death on thrombotic microangiopathy, a condition where small blood clots damage organs, and investigators tied it directly to the therapy.

The therapy targeted a rare genetic condition, and the girl’s case was part of a small clinical trial run through Shanghai Jiao Tong University School of Medicine and Xinhua Hospital. Investigators found the hospital had approved the treatment despite what Caixin described as insufficient safety evidence, pointing to breakdowns in both testing and ethics review before the girl was ever treated.

Animal Testing Raised Red Flags That Never Reached the Hospital

Before any human received the therapy, researchers ran safety tests on non-human primates. Those tests produced warning signals. Shanghai Daily reported that Qiu’s team never promptly told the hospital’s clinical-study leader about the concerning results, so the warnings went unheeded when the girl’s treatment moved forward. Tech Times reported the unheeded findings specifically involved monkey test subjects showing signs of trouble before human dosing began.

Parents reportedly asked about risks like liver damage during the consent process and were given reassurance rather than a full picture of what the animal data showed, according to social media accounts tied to the case. The formal investigation found the informed-consent paperwork did not clearly emphasize the risk of death, a gap confirmed by both CCTV reporting and Shanghai authorities cited in later coverage.

The Death Stayed Out of the Published Study

CCTV reporting, summarized by the Seattle Times, said investigators determined the scientists never disclosed the child’s death in a research paper published in February. Nature’s coverage of the Shanghai investigation reached the same conclusion, reporting that the published study omitted the death entirely. Investigators did not find evidence that the researchers faked their data, according to Shanghai Daily; the failures centered on safety reporting, ethics review, consent, and disclosure rather than fabricated results.

Firings and a Five-Year Ban

Qiu Zilong, identified as deputy director of the Songjiang research institute involved in the trial, was fired. He also received a five-year ban from government-funded science and technology projects. A second researcher at Xinhua Hospital was dismissed as well, and additional personnel faced disciplinary action. These are administrative sanctions announced through Chinese state media rather than findings from an open court proceeding.

A Pattern China Has Seen Before

This case echoes the 2018 scandal involving scientist He Jiankui, who used CRISPR to edit human embryos and was later found to have falsified ethics documents and failed to properly disclose risks to the families involved. That case led to new national rules in 2019 and further ethics guidance in 2022 and 2023, specifically aimed at tightening oversight of high-risk biotechnology research.

Researchers studying China’s regulatory system point to a recurring structural problem: oversight gets split among scientists, hospitals, ethics boards, regulators, and journals, yet the public spotlight almost always lands on one scientist. That pattern is playing out again. Shanghai’s punishment of two researchers addresses individual accountability, but it does not by itself fix the fragmented review process that let warning signs go unheeded in the first place.

For American readers watching the race to develop gene therapies, the case is a blunt reminder of why rigorous, independent ethics review exists before any human being, let alone a child, receives an experimental treatment. Cutting corners on animal-safety data or informed consent does not just risk a scientist’s career. It costs lives.

Shanghai authorities have not released the full investigation report, the underlying clinical records, or the consent documents themselves. What has been made public, through state media and the disciplinary actions against Qiu and his colleague, lays out a clear sequence: a known risk, a warning ignored, a child’s death, and a published study that left the outcome out entirely.

Sources:

insiderpaper.com, seattletimes.com, dongascience.com, fiercebiotech.com, bloomberg.com, biz.chosun.com, nampa.org, citynewsservice.cn, cnn.com, geneonline.com, sage.cnpereading.com

© featuredheadlines.com 2026. All rights reserved.